389650 — NextBioMedical Co Cashflow Statement
0.000.00%
Last trade - 00:00- KR₩700bn
- KR₩681bn
- KR₩10bn
Annual cashflow statement for NextBioMedical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -5,732 | -7,522 | 2,860 |
| Depreciation | |||
| Amortisation | |||
| Non-Cash Items | -253 | 3,939 | -3,998 |
| Unusual Items | |||
| Purchased R&D | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | -2,687 | -1,045 | -554 |
| Change in Accounts Receivable | |||
| Change in Inventories | |||
| Change in Prepaid Expenses | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Change in Other Liabilities | |||
| Other Operating Cash Flow | |||
| Cash from Operating Activities | -8,208 | -4,160 | -1,201 |
| Capital Expenditures | -195 | -64.5 | -439 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | -10,750 | 4,171 | -25,921 |
| Sale of Fixed Assets | |||
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Other Investing Cash Flow | |||
| Cash from Investing Activities | -10,945 | 4,106 | -26,361 |
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 95.2 | 974 | 28,349 |
| Foreign Exchange Effects | |||
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | -19,002 | 888 | 1,048 |